Bristol-Myers Squibb (BMY), racing to convince shareholders to back its planned $74 billion acquisition of Celgene (CELG), could have its plans derailed by a pair of hugely influential financial advisers.

ISS and Glass Lewis, two global firms that make recommendations to institutional investors, are yet to weigh in on the potential merger. Together they claim a roughly 97 percent share of market for shareholder advice, and their verdict on the deal could spoil the largest pharmaceutical acquisition in history.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy